MillerKnoll (NASDAQ:MLKN – Get Free Report) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Monday.
MillerKnoll Stock Up 1.6 %
Shares of NASDAQ MLKN opened at $24.68 on Monday. The company has a quick ratio of 0.92, a current ratio of 1.53 and a debt-to-equity ratio of 0.93. MillerKnoll has a 52 week low of $19.10 and a 52 week high of $31.73. The firm’s fifty day moving average is $28.30 and its 200 day moving average is $27.36. The company has a market cap of $1.77 billion, a price-to-earnings ratio of 22.23, a PEG ratio of 0.99 and a beta of 1.18.
MillerKnoll (NASDAQ:MLKN – Get Free Report) last issued its earnings results on Thursday, September 19th. The company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.04). MillerKnoll had a return on equity of 10.94% and a net margin of 2.27%. The firm had revenue of $861.50 million during the quarter, compared to analysts’ expectations of $889.38 million. During the same period in the previous year, the firm earned $0.37 earnings per share. The firm’s quarterly revenue was down 6.1% compared to the same quarter last year. On average, equities research analysts expect that MillerKnoll will post 2.21 earnings per share for the current year.
Institutional Inflows and Outflows
About MillerKnoll
MillerKnoll, Inc researches, designs, manufactures, and distributes interior furnishings worldwide. It operates through three segments: Americas Contract, International Contract & Specialty, and Global Retail. The company also provides seating products, furniture systems, other freestanding furniture elements, textiles, leather, felt, home furnishings and related services, casegoods, storage products, as well as residential, education, and healthcare furniture solutions.
See Also
- Five stocks we like better than MillerKnoll
- 3 Warren Buffett Stocks to Buy Now
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Why Invest in High-Yield Dividend Stocks?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is a buyback in stocks? A comprehensive guide for investors
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for MillerKnoll Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MillerKnoll and related companies with MarketBeat.com's FREE daily email newsletter.